Image pharmaphorum Editor Views & Analysis Rethinking trial engagement and recruitment starts with pati... With countless media stories regarding COVID-19 published over a period of several years, it was obvious that people around the globe were tuned in to every step of the fight against the pa Views & Analysis It’s time to tackle the gender health gap with technology The potential for technology to transform the way we deliver healthcare is nothing new. R&D Now is the time for pharma to help solve bias in clinical tr... Pharma has a great opportunity ahead of it when it comes to conducting representative clinical trials. Views & Analysis Transforming oncology outcomes through data and digital The healthcare industry is evolving rapidly, with data and digital technologies transforming everyday communications as we know them. Load more results
Views & Analysis Rethinking trial engagement and recruitment starts with pati... With countless media stories regarding COVID-19 published over a period of several years, it was obvious that people around the globe were tuned in to every step of the fight against the pa
Views & Analysis It’s time to tackle the gender health gap with technology The potential for technology to transform the way we deliver healthcare is nothing new.
R&D Now is the time for pharma to help solve bias in clinical tr... Pharma has a great opportunity ahead of it when it comes to conducting representative clinical trials.
Views & Analysis Transforming oncology outcomes through data and digital The healthcare industry is evolving rapidly, with data and digital technologies transforming everyday communications as we know them.
Patients Making direct-to-patient work, with Matt Wadyka Matt Wadyka, chief client strategy officer at Inizio Medical, spoke to pharmaphorum about the ins and outs of direct-to-patient programmes in pharma.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
